

The Royal Women's Hospital presents:

Cervical and other HPV related cancers – not yet beaten?

AOGIN AUSTRALIA

HPV vaccines

HPV DNA testing

Changes & progress in cervical cytology screening

Anal cancer and potential screening

Oropharyngeal cancers

Thursday 14 October 2010

Bio21 Institute

30 Flemington Road

Parkville Victoria

An initiative of AOGIN



the women's
the royal women's hospital
victoria australia

Professor Joel Palefsky

Keynote speaker



Joel Palefsky

M.D., C.M., F.R.C.P.(C).

Professor of Medicine at the University of California San Francisco School of Medicine. Prof Palefsky completed his undergraduate medical training and training in Internal Medicine at McGill University and completed his fellowship in Infectious Diseases at Stanford University in 1989. He then joined the faculty at the University of California, San Francisco, where he remains to this day.

He is an internationally recognized expert on the molecular biology, treatment, pathogenesis and natural history of anogenital human papillomavirus infections, particularly in the setting of HIV infection. He is the Director of the world's first clinic devoted to prevention of anal cancer, the Anal Neoplasia Clinic at the UCSF Cancer Center.

He has pioneered diagnostic and treatment methods for anal intraepithelial neoplasia (AIN) and has been an advocate for screening and treatment of AIN in high-risk populations to prevent anal cancer. He is the chair of the HPV Working Group of the U.S. National Cancer Institute-supported AIDS Malignancy Consortium. Prof Palefsky is the leader of the Pathways to Careers in Clinical and Translational Research program at the University of California San Francisco, a program designed to train medical and allied health sciences students in the skills needed to pursue careers in clinical and translational research. He is a member of the board of the American Society for Colposcopy and Cervical Pathology (ASCCP) and co-chair of the ASCCP Special Populations Working Group. He is the author of over 220 publications.

Program

8.00am–8.40am **Arrival and registration**

8.40am–8.50am **Welcome and program introduction**

Session 1 – HPV vaccines: what are the indications for males?

Chair: Professor Suzanne Garland

8.50am–9.10am Anal cancer – what do we know, should we be screening and how?
Associate Professor Richard Hillman, University of Sydney

9.10am–9.40am What is the latest data on men from the phase 3 HPV vaccine clinical trials?
Professor Joel Palefsky, University of California San Francisco School of Medicine

9.40am–10.00am The epidemiology of anal cancer in Australia:
implications for the development of anal cancer prevention services
Professor Andrew Grulich, University of New South Wales

10.00am–10.20am Vaccine efficacy against genital warts in Australia
Professor Christopher Fairley, Melbourne Sexual Health

10.20am–10.50am Morning tea

10.50am–11.10am Psychological impact of screening for cervical cancer or HPV infection
Dr Marie Pirota, University of Melbourne

11.10am–11.30am What is modelling telling us about vaccination of males?
Dr Jane Hocking, University of Melbourne

11.30am–12.00pm Discussion

Session 2 – HPV vaccines

Chair: Professor Marian Pitts

12.00pm–12.20pm How we best talk to males about HPV and HPV vaccines?
Professor Marian Pitts, Australian Research Centre in Sex, Health & Society

12.20pm–12.40pm HPV vaccination in general practice: where to now?
Associate Professor Danielle Mazza, Monash University

12.40pm–1.00pm What is the end of study data for the bivalent and quadrivalent vaccines?
Dr Jeffrey Tan, the Royal Women's Hospital

1.00pm–1.15pm Discussion

1.15pm–2.00pm Lunch

Program continued

Session 3 – Oropharyngeal

Chair: Dr Julia Brotherton

2.00pm–2.20pm	HPV: A new type of oropharyngeal cancer Dr Tim Iseii, Royal Melbourne Hospital
2.20pm–2.40pm	Recurrent respiratory papillomatosis, HPV and vaccination Dr Daniel Novakovic, The Children's Hospital at Westmead, Sydney
2.40pm–3.00pm	Oropharyngeal cancers – Australian data Dr Angela Hong, University of Sydney
3.00pm–3.15pm	Discussion
3:15pm–3:45pm	Afternoon tea

Session 4 – Vaccines and screening in the vaccine era

Chair: Dr Marie Pirota

3.45pm–4.00pm	Australian HPV genotype prevalence, the WHINURS data Professor Suzanne Garland, the Royal Women's Hospital
4.00pm–4.20pm	How might cervical screening change in the future? Associate Professor Marion Saville, Victorian Cytology Service
4.20pm–4.40pm	HPV vaccination coverage in Australia: achievements and challenges Dr Julia Brotherton, Victorian Cervical Cytology Registry
4.40pm–5.10pm	Management of HPV and HIV/ Vaccination of HIV (+) Professor Joel Palefsky, University of California San Francisco School of Medicine

Session 5 – Q&A/ask the expert session

Chair: Professor Suzanne Garland

5.10pm–6.00pm	All speakers
6.00	Close

Registration

To register your attendance please go to www.thewomens.org.au/ccnyb
For all enquires please contact ccnyb@thewomens.org.au

Medical Practitioners

\$150 (inc GST) Early bird rate for registrations received prior to 6 September 2010

\$200 (inc GST) for registrations after 6 September 2010

Trainees/non-medical

\$100 (incl GST) Early bird rate for registrations received prior to 6 September 2010

\$150 (incl GST) for registrations after 6 September 2010

Sponsored by

CSL Biotherapies



GlaxoSmithKline
Vaccines



Supported by

